DalCor is set to increase enrolment in its ongoing dal-GenE trial, a Phase III clinical study of dalcetrapib, from 5000 to 6000 patients.

The development is based on better than expected enrolment results witnessed by dal-GenE, which has so far randomised a total of 4300 patients around five months ahead of enrolment projections.

The randomised, placebo-controlled trial will enrol 6000 patients recently hospitalised with acute coronary syndrome (ACS).

“The success of the enrolment has provided the opportunity to reconsider initial assumptions to strengthen the trial design.”

Patients who have expressed the AA genotype at variant rs1967309 in the ADCY9 gene – as determined by an investigational companion diagnostic test developed by Roche Molecular Systems (RMS)- will also be included in the trial.

The trial’s primary endpoint is the time to first occurrence of any component of the composite of cardiovascular death, myocardial infarction (heart attack) and stroke.

It is currently being conducted in more than 700 sites in 33 countries worldwide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

dal-GenE executive committee chair Dr Jean-Claude Tardif said: “The success of the enrolment has provided the opportunity to reconsider initial assumptions to strengthen the trial design.

“As a result, the sample size of the dal-GenE study will be increased to 6000 patients while maintaining the originally projected recruitment timelines of year-end 2018.

“The prospect of precision medicine for cardiovascular health has been embraced by our colleagues around the world.”

With the expansion of patient number, DalCor also aims to increase the precision of the trial.

Dalcetrapib is a medicine designed to target cardiovascular diseases.